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Ajay J. Kirtane, MD, SM, Christopher R. Kelly, MDA mong behavioral risk factors for adversehealth outcomes, smoking stands alone inits public health impact, accounting for
nearly 500,000 (or 1 in 5) deaths in the United States
annually (1). In the aftermath of many well-
chronicled legal battles with the tobacco industry,
the causality between smoking and adverse cardio-
vascular events became unquestionable, and smoking
cessation is a major goal of guideline-directed medi-
cal therapy for both primary and secondary preven-
tion of coronary heart disease.
Nonetheless, it is important to recognize a curious
phenomenon published within the cardiovascular
literature known as the “smoker’s paradox”: an inter-
mittently observed association between smoking sta-
tus and improved short-term outcomes in various
cardiovascular disease states. The smoker’s paradox
was ﬁrst noted in early studies on the natural history
of acute myocardial infarction (MI) (2) and later
conﬁrmed in studies of ﬁbrinolysis, such as GUSTO-I
(Global Utilization of Streptokinase and Tissue Plas-
minogen Activator for Occluded Coronary Arteries) (3).
More recent data suggest a similar phenomenon
among patients with acute stroke (4) or cardiac
arrest (5).
The smoker’s paradox often is used to illustrate the
differences between association and causality in
clinical epidemiology. For example, compared with
nonsmokers, smokers presenting with acute MI are
consistently younger and have fewer atherosclerotic
risk factors and other comorbid conditions, such
as diabetes and hypertension. Thus, some of the*Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.crude (unadjusted) association between smoking and
improved outcomes is clearly attributable to con-
founding; when multivariable analyses account for
known confounders, the apparent beneﬁt of smoking
is uniformly attenuated. Some observational studies,
however, have found a residual survival advantage
among smokers, even after multivariable adjustment.
In GUSTO-I, for example, the odds of 30-day mortality
were 25% lower among smokers even after adjusting
for age, sex, blood pressure, time to therapy, and other
covariates (3). A similar phenomenon associating
smoking with improved in-hospital mortality was
noted among nearly 300,000 patients in the National
Registry of Myocardial Infarction database (6).
Of course, the marked increase in long-term mor-
tality attributable to smoking would completely negate
any modest improvement in short-term outcomes;
smokers lose, on average, a full decade of life (7).
Nonetheless, the smoker’s paradox raises interesting
pathophysiologic questions: First, does it point to a
mechanism by which smokers accrue some short-term
beneﬁt? Second, would such a mechanism be relevant
in the era of modern-day antithrombotic therapies?
Regarding the ﬁrst question, several studies have
demonstrated that ﬁbrinolytic therapy yields better
epicardial vessel patency (8) andmyocardial perfusion
(9) among smokers compared with nonsmokers.
Therefore, smoking may result in either coronary oc-
clusion that is richer in clot and more amenable to
ﬁbrinolysis or, in some other way, enhance respon-
siveness to these medications. This mechanism is less
relevant in the era of primary percutaneous coronary
intervention (PCI) as thedominant reperfusion therapy
for acute MI (10). However, recent data have demon-
strated a speciﬁc pharmacodynamic enhancement of
platelet inhibition by clopidogrel among smokers (11),
which may hold important implications for patients
treated with PCI, given that clopidogrel remains the
dominant P2Y12 inhibitor in clinical practice.
In this issue of the Journal, Zhang et al. (12)
examined smoking status and outcomes among the
1,800 patients in the SYNTAX (Synergy between
PCI with Taxus and Cardiac Surgery) trial, which
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1117randomized patients with severe coronary artery
disease (CAD) to PCI with paclitaxel-eluting stents or
coronary artery bypass grafting (CABG). The authors
found no effect of baseline smoking status on 5-yearSEE PAGE 1107rates of death/MI/stroke in unadjusted analyses,
suggesting that, at best, smokers had the same risk as
nonsmokers, who were a decade older and more
likely to have diabetes and hypertension. Unlike in
prior studies, however, these investigators reported
smoking status not only at baseline but also at 6
months and 1, 3, and 5 years. The dynamic nature of
smoking status in this population of patients with
complex multivessel CAD is alone noteworthy. At
presentation, 20.2% of patients actively smoked. Over
5 years, most of these smokers quit, usually prior to 6-
month follow-up, yet of those who reported cessation
at 6 months, >25% resumed smoking during 5-year
follow-up. These ﬁndings are sobering and empha-
size that our efforts at smoking cessation for our
patients with the most severe CAD need to be
continuous, not myopically targeted only to the time
of initial revascularization.
Because smoking cessation markedly attenuates
mortality risk (7), especially among younger patients,
the failure of earlier studies to include subsequent
assessments of smoking status may have contributed
to the apparent survival beneﬁt among baseline
smokers, who may have quit smoking after the index
event and were younger and otherwise healthier than
baseline nonsmokers. Indeed, when smoking was
considered as a time-varying covariate in SYNTAX
(allowing for smokers who quit to be analyzed as
nonsmokers during the interval in which they quit),
smoking was associated with a higher rate of death/
MI/stroke at 5 years, an effect driven by an 86%
greater hazard of MI. After adjusting for other base-
line covariates, the association between smoking and
death/MI/stroke became stronger and was evident as
early as 6 months. Notably, the increased incidence of
MI was present both among CABG- and PCI-treated
patients, with no protective effect of smoking onstent thrombosis in this clopidogrel-treated patient
population.
Importantly, the SYNTAX trial examined a po-
pulation of patients with predominantly stable
CAD. Therefore, these ﬁndings cannot be compared
directly to the acute MI studies that ﬁrst described the
smoker’s paradox. Additionally, because smokers
requiring revascularization typically have less exten-
sive disease than nonsmokers (13), the smokers with
multivessel disease included in the SYNTAX trial likely
had worse outcomes than smokers in other trials.
Nonetheless, this analysis provides compelling evi-
dence that for patients undergoing coronary revascu-
larization, continuing to smokemarkedly increases the
risk of subsequent adverse outcomes, especially MI.
In this SYNTAX cohort, smoking was more haz-
ardous than a 10-year increase in age and had an
adjusted hazard exceeding that of the primary study
comparison (of PCI vs. CABG). These 2 observations
are vitally important from a public health perspec-
tive. As scientists, we often focus on the relative
merits of medical and device-based therapies, yet
from a global perspective, the realized effects of these
marginal differences is likely far less than what could
be achieved through successful interventions that
reduce the rate of smoking. It is encouraging in this
regard that cigarette smoking among adults in the
United States is lower than ever, with a decline from
20.9% in 2005 to 17.8% in 2013 (14), but we clearly
have a long way to go. As clinicians treating individ-
ual patients, it is critical for us to put these data in
perspective, continuing to focus assiduously on
smoking cessation with all patients, and remem-
bering that relapses are common, even in high-risk
patients who have undergone multivessel coronary
revascularization.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Ajay J. Kirtane, Columbia University Medical Center,
Center for Interventional Vascular Therapy, 161 Fort
Washington Avenue, Herbert Irving Pavilion, 6th
Floor, New York, New York 10032. E-mail: akirtane@
columbia.edu.RE F E RENCE S1. U.S. Health and Human Services. The Health
Consequences of Smoking—50 Years of Prog-
ress: A Report of the Surgeon General. Atlanta,
GA: U.S. Department of Health and Human
Services, CDC. Available at: http://www.sur
geongeneral.gov/library/reports/50-years-of-
progress/. Accessed November 2, 2014.
2. Kitchin AH, Pocock SJ. Prognosis of patients
with acute myocardial infarction admitted to acoronary care unit. I: survival in hospital. Br Heart
J 1977;39:1163–6.
3. Barbash GI, Reiner J, White HD, et al. Evaluation
of paradoxic beneﬁcial effects of smoking in pa-
tients receiving thrombolytic therapy for acute
myocardial infarction: mechanism of the “smoker’s
paradox” from the GUSTO-I trial, with angio-
graphic insights. Global Utilization of Streptoki-
nase and Tissue-Plasminogen Activator forOccluded Coronary Arteries. J Am Coll Cardiol
1995;26:1222–9.
4. Ali SF, Smith EE, Bhatt DL, Fonarow GC,
Schwamm LH. Paradoxical association of smoking
with in-hospital mortality among patients
admitted with acute ischemic stroke. J Am Heart
Assoc 2013;2:e000171.
5. Pollock JS, Hollenbeck RD, Wang L, Janz DR,
Rice TW, McPherson JA. A history of smoking is
Kirtane and Kelly J A C C V O L . 6 5 , N O . 1 1 , 2 0 1 5
Clearing the Air on the “Smoker’s Paradox” M A R C H 2 4 , 2 0 1 5 : 1 1 1 6 – 8
1118associatedwith improvedsurvival inpatients treated
with mild therapeutic hypothermia following car-
diac arrest. Resuscitation 2014;85:99–103.
6. Gourlay SG, Rundle AC, Barron HV. Smoking
and mortality following acute myocardial infarc-
tion: results from the National Registry of
Myocardial Infarction 2 (NRMI 2). Nicotine Tob Res
2002;4:101–7.
7. Jha P, Ramasundarahettige C, Landsman V,
et al. 21st-century hazards of smoking and bene-
ﬁts of cessation in the United States. N Engl J Med
2013;368:341–50.
8. de Chillou C, Riff P, Sadoul N, et al. Inﬂuence of
cigarette smoking on rate of reopening of the
infarct-related coronary artery after myocardial
infarction: a multivariate analysis. J Am Coll Car-
diol 1996;27:1662–8.9. Kirtane AJ, Martinezclark P, Rahman AM, et al.
Association of smoking with improved myocar-
dial perfusion and the angiographic character-
ization of myocardial tissue perfusion after
ﬁbrinolytic therapy for ST-segment elevation
myocardial infarction. J Am Coll Cardiol 2005;45:
321–3.
10. Weisz G, Cox DA, Garcia E, et al. Impact of
smoking status on outcomes of primary coronary
intervention for acute myocardial infarction—the
smoker’s paradox revisited. Am Heart J 2005;150:
358–64.
11. Gurbel PA, Bliden KP, Logan DK, et al. The in-
ﬂuence of smoking status on the pharmacokinetics
and pharmacodynamics of clopidogrel and prasu-
grel: the PARADOX study. J Am Coll Cardiol 2013;
62:505–12.12. Zhang Y-J, Iqbal J, van Klaveren D, et al.
Smoking is associated with adverse clinical out-
comes in patients undergoing revascularization
with PCI or CABG: the SYNTAX trial at 5-year
follow-up. J Am Coll Cardiol 2015;65:1107–15.
13. Hasdai D, Garratt KN, Grill DE, Lerman A,
Holmes DR Jr. Effect of smoking status on the long-
term outcome after successful percutaneous coro-
nary revascularization.NEnglJMed1997;336:755–61.
14. Jamal A, Agaku IT, O’Connor E, King BA,
Kenemer JB, Neff L. Current cigarette smoking
among adults—United States, 2005–2013. MMWR
Morb Mortal Wkly Rep 2014;63:1108–12.KEY WORDS acute coronary syndrome(s),
coronary artery disease, smoking, tobacco
